| HOME >> MEDICINE >> TECHNOLOGY |
-6,338Total cash and marketable securities
$
257,730$
70,449DebtNew Revolving Credit Facility
$
25,000$
220,000Term loan A Facility
2,108,9642,185,520New Term Loan B Facility
1,265,854-Senior notes
4,230,4284,228,480Convertible notes
-17,011Other
--7,630,2466,651,011Less: Current portion
(207,688)(111,250)$ 7,422,558$ 6,539,7615.2Summary of Cash Flow StatementThree Months EndedSeptember 30,20122011Cash flow provided by (used in):Net cash provided by (used in) operating activities (GAAP)
$
,824$
73,707Restructuring and acquisition-related costs (c)
47,47725,372Payment of accrued legal settlements
37,739-Payment of Accreted Interest on Convertible Debt
-3,362Tax Benefit from Stock Options Exercised(a)
2,3672,042Working Capital change related to Business Development Activities
--Non-Cash adjustments to Income Taxes Payable
--Changes in working capital related to restructuring and acquisition-related costs(c)
(13,251)3,918Adjusted cash flow from operations (Non-GAAP)(b)
$
241,156$
208,401Proceeds from sale of intangible assets
--Adjusted cash flow from operations (Non-GAAP) (b)
$
241,156$
208,401(a) Includes stock option tax benefit which will reduce taxes in future periods.(b) See footnote (a) to Table 2a.(c) Total Restructuring and Acquisition-related costs cash payments of $34,226 are broken down as follows:Project TypeAmount PaidiNova
5,736Intellectual Property Migration
5,390
'/>"/>
| SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2012 PR Newswire. All rights reserved |